Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06641544
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-11
Brief Title:
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IFANS
Brief Summary:
This study is to explore the efficacy and safety of the first-line treatment of HER2 positive recurrentmetastatic breast cancer with Inetetamab combined with Pertuzumab or Pyrotinib combined with chemotherapy hoping to have better clinical benefits and provide a new treatment mode for targeted treatment
Detailed Description:
In terms of the anti-HER2 mechanism the binding sites of Inetetamab and Trastuzumab are located in the extracellular domain IV while the binding site of Pertuzumab is located in the conserved domain II inhibiting HER2 phosphorylation and blocking downstream signaling pathways The binding site of Pyrotinib is located in the intracellular tyrosinase active domain which competes with ATP to block HER2 autophosphorylation and activation Inetetamab combined with Pertuzumab dual target blocks HER2 dimer formation while Inetetamab combined with Pyrotinib dual target inhibition can produce synergistic enhancement of anti-HER2 effect This study is to explore the efficacy and safety of the first-line treatment of HER2 positive recurrentmetastatic breast cancer with Inetetamab combined with Pertuzumab or Pyrotinib combined with chemotherapy hoping to have better clinical benefits and provide a new treatment mode for targeted treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None